Abstract
Adherence-specific coaching by a Case Manager (CM) did not further improve the level of medication adherence achieved in the original C-STOP study. Importantly, these results can inform adherence strategies in future intervention studies by identifying an "intervenable ceiling" and the significant impact of comorbid conditions like depression.
Introduction
Osteoporosis is frequently characterized as a "silent disease" because it often remains undiagnosed until a patient experiences a debilitating fracture. Even when a fracture provides a clear clinical signal for intervention, medication adherence remains a persistent challenge. Previous research from the C-STOP (Comparing Strategies Targeting Osteoporosis to Prevent Fractures) trial demonstrated that a nurse case manager could significantly increase treatment initiation. However, adherence rates—defined as taking medication correctly at least 80% of the time—plateaued at approximately 79%. This study explores a "Single Arm Variation" of that trial, testing whether more intensive, person-centered telephone coaching specifically focused on adherence could break through this established plateau.
Methods
This prospective observational cohort study was conducted in Edmonton, Canada, targeting community-dwelling adults aged 50 and older. Participants were recruited following a recent upper-extremity fracture (such as the wrist or shoulder) and were not currently on osteoporosis medication.
The core intervention involved a trained Case Manager who arranged clinic visits for education and bone mineral density (BMD) testing, and initiated treatment for high-risk patients. The specific "Variation" in this study involved more frequent telephone follow-ups at 3, 6, and 12 months. These calls utilized person-centered communication to provide tailored coaching and advice based on the patient's specific adherence and persistence patterns. Adherence was validated through a combination of self-reporting and pharmacy-fill records.
Key Insights
The Adherence Ceiling
Despite the resource-intensive nature of the additional coaching, the 12-month adherence rate (77.3%) was nearly identical to the 79% observed in the original C-STOP trial. This suggests that there may be a limit to how much external coaching can influence patient behavior in this specific population, representing an "intervenable ceiling."
Persistence vs. Adherence
The study revealed a high rate of treatment persistence (95.5% remained on therapy at one year) but lower adherence (77.3% took the medication correctly). This indicates that while patients are willing to stay on a treatment plan, the complex requirements for taking oral bisphosphonates—which often involve specific timing and posture rules—remain a significant hurdle.
The Mental Health Barrier
Depression emerged as the most significant predictor of non-adherence. Patients with self-reported depression were nearly 10 times more likely to be non-adherent (Adjusted Odds Ratio: 9.8; 95% CI, 1.2–81.5). This suggests that osteoporosis management must be integrated with mental health support to be truly effective.
Results
From an initial screening of 390 individuals, 84 participants were enrolled. Of the 30 participants prescribed oral bisphosphonates, 73.3% initiated treatment within the first three months. At the 12-month follow-up, the adherence rate was 77.3%, and the persistence rate was 95.5%. Among participants not prescribed bisphosphonates, supplement use was high, with 62.8% taking calcium and 93.0% taking Vitamin D.
Conclusion
While intensive coaching by a Case Manager ensures high rates of treatment initiation and persistence, it does not appear to incrementally improve adherence beyond levels established in less intensive models. The strong correlation between depression and non-adherence highlights a critical area for future work. Interventions may need to move beyond coaching to include integrated mental health support or simpler dosing regimens to address the barriers of forgetfulness and comorbid psychological distress.
Summary updated